A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

• Status: Unknown status
• Trial end date: 2017-06-01
• Target enrollment: 0
• Participant gender: All

Summary

A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with gastric carcinoma by estimating progression free survival (PFS) in each treatment arm.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hebei Tumor Hospital
• Treatments: Docetaxel; Raltitrexed

Criteria

Inclusion Criteria:

1. Signed informed consent form

2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;

3. Histologically or cytologically confirmed gastric cancer;

4. The first-line chemotherapy failure (required containing 5-fluorouracil)

5. At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors )

6. Life expectancy of at least 3 months;

Exclusion Criteria:

1. Received any prior treatment including Raltitrexed;

2. Active or uncontrolled infection;

3. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;

4. Pregnant or lactating women.